mRNA Cancer Vaccines: Hope, Approaches & Future Outlook

mRNA Vaccines: A New Hope for Cancer Treatment

The revolutionary mRNA technology that propelled COVID-19 vaccines into the spotlight is now turning its focus back to its original ambition: cancer therapy. With over 120 studies currently underway, ranging from early to advanced phases, researchers are increasingly optimistic about the potential of mRNA vaccines to transform cancer treatment. This approach isn’t entirely new; the groundwork for mRNA technology was initially laid with cancer in mind.

The fundamental principle behind mRNA cancer vaccines lies in harnessing the body’s own immune system. As Antonie Müller, Professor of Cell Therapy and Transfusion Medicine at MedUni Vienna, explains, “Degenerate cells have characteristics that the immune system responds to, but the immune reaction in cancer is often too weak.” mRNA vaccines aim to amplify this immune response by delivering instructions – the mRNA blueprint – to the body’s cells to produce these cancer-specific characteristics. “And in a much higher dose than that caused by the tumor itself,” adds Ewald Wöll, President of the Austrian Society for Hematology and Medical Oncology (OeGHO).

Two Approaches to mRNA Cancer Vaccination

Currently, two primary strategies are being explored in clinical trials. The first involves creating vaccines that target characteristics common to a specific type of cancer. A phase III study is currently evaluating a vaccine for melanoma that incorporates four features found in 90% of patients with this cancer type. This approach offers the potential for a broadly applicable therapy for a given cancer subtype.

The second, more personalized approach involves analyzing a sample of a patient’s tumor to identify its unique genetic mutations. The mRNA blueprint for these individual tumor characteristics is then packaged into a vaccine tailored specifically to that patient. Researchers anticipate that artificial intelligence (AI) could play a crucial role in the future, helping to identify the most effective targets for these personalized vaccines.

“Both are valid approaches,” says Müller. The subtype-targeting strategy is methodologically simpler and provides an “off-the-shelf” therapy, while the individualized approach, though more complex and costly, offers the potential for highly targeted treatment.

Which Cancers Might Benefit?

mRNA vaccination is expected to be most effective in immunogenic tumors – those that already elicit some immune response, such as melanoma and certain types of lung cancer – and those that respond to other immunotherapies. However, the technology also offers a glimmer of hope for cancers traditionally considered “immunologically cold,” meaning they don’t readily trigger an immune response. Wöll highlights a small but promising study in advanced pancreatic cancer, where mRNA vaccination significantly extended survival in half of the patients.

Despite the excitement, experts emphasize that surgery remains the most effective treatment for many cancers. Müller explains that mRNA vaccination is most likely to be beneficial when used in conjunction with other therapies. “In order for the mRNA vaccination to work, large tumors must be removed or reduced in size through surgery, radiation or chemotherapy. Then the mRNA vaccination can improve the response or prevent or delay the recurrence of tumors.” He adds that mRNA vaccination is “particularly suitable for types of cancer with a high risk of relapse.”

Overcoming Immune Suppression

A significant challenge in cancer treatment is the ability of tumors to evade the immune system. Tumors often surround themselves with cells and release substances that suppress immune responses. Wöll notes that overcoming this immune suppression is unlikely to be achieved with mRNA vaccination alone. “We see unlikely that this blockage will be overcome by the mRNA vaccination alone; a second partner will usually be needed.” current studies are combining mRNA vaccination with checkpoint inhibitors and other innovative therapies designed to make cancer cells more vulnerable to the immune system.

Looking Ahead: Timelines and Regulatory Hurdles

While mRNA vaccination holds significant promise, it’s not expected to be a universal cure for cancer. Both experts agree that it represents a valuable addition to the existing cancer treatment arsenal. The timeline for widespread availability remains uncertain. The first phase III studies are anticipated to be completed by 2029, which is often cited as a potential date for initial approvals. Recently, a study on HPV-positive head and neck tumors received “fast track” status from the US Food and Drug Administration (FDA), potentially accelerating its path to approval. However, experts caution against making definitive predictions about regulatory approval at this stage.

As the field continues to evolve, mRNA cancer vaccines represent a significant step forward in personalized medicine, offering a new avenue for harnessing the power of the immune system to fight this complex disease.